Sign In
Buy CABA
$3.58
-0.100 (-2.72%)
At Close: Jun 03, 2026
Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference
08:00am, Wednesday, 29'th Jan 2025
PHILADELPHIA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie
Cabaletta Bio: Finding Optimism In Dire Straits
02:28pm, Monday, 06'th Jan 2025
Cabaletta Bio, Inc.'s CD19-directed CAR T-cell therapy shows early promise in treating autoimmune diseases, despite limited patient numbers and follow-up time. Financially, Cabaletta Bio has enough ca
Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash
11:41am, Tuesday, 22'nd Oct 2024
I am buying Cabaletta Bio shares as a speculative play on upcoming clinical trial updates for innovative CAR-T therapies. Despite high volatility in 2024 and the potential for total investment loss, t
Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024
04:30pm, Wednesday, 25'th Sep 2024
PHILADELPHIA, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapi
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
08:00am, Wednesday, 28'th Aug 2024
PHILADELPHIA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie
Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
07:00am, Thursday, 08'th Aug 2024
– Nine patients enrolled as of August 5, 2024 across the RESET™ clinical development program, including four since EULAR in June, with 22 U.S. clinical sites now enrolling –
Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
07:00am, Thursday, 08'th Aug 2024
– Nine patients enrolled as of August 5, 2024 across the RESET™ clinical development program, including four since EULAR in June, with 22 U.S. clinical sites now enrolling –
Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum
08:00am, Tuesday, 02'nd Jul 2024
PHILADELPHIA, July 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie
Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment
01:42pm, Friday, 28'th Jun 2024
Cabaletta Bio focuses on autoimmune diseases with a potential best-in-class cell therapy, CABA-201, showing promise in early studies. It's stock price rose >$25 due to positive data produced by a drug
Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201
02:00am, Friday, 14'th Jun 2024
– No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 –
Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
07:00am, Wednesday, 15'th May 2024
– No CRS or ICANS of any grade observed during the 28-day DLT observation window for either of the first patients dosed with CABA-201 in the RESET-Myositis™ and RESET-SLE™ trials –
Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
08:00am, Monday, 13'th May 2024
PHILADELPHIA, May 13, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
07:00am, Thursday, 21'st Mar 2024
– First patient dosed with CABA-201 in the RESET™ (REstoring SElf-Tolerance) clinical trial program – – Initial clinical data from each of the first patients in the RESET-Myositis™ and RESET
Cabaletta Bio to Participate in Upcoming Investor Conferences in March
08:00am, Tuesday, 27'th Feb 2024
PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
04:30pm, Thursday, 01'st Feb 2024
PHILADELPHIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie
